Reprint

Radiolabeled Compounds for Diagnosis and Treatment of Cancer

Edited by
December 2021
262 pages
  • ISBN978-3-0365-2427-6 (Hardback)
  • ISBN978-3-0365-2426-9 (PDF)

This book is a reprint of the Special Issue Radiolabeled Compounds for Diagnosis and Treatment of Cancer that was published in

Chemistry & Materials Science
Medicine & Pharmacology
Summary

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
positron emission tomography (PET); pyrazoles; fluorine-18; radionuclides; PET probes; imaging pharmaceuticals; hypopharyngeal cancer; 188Re-liposome; repeated therapy; NGS; microRNA; aprepitant; radiopharmaceuticals; neurokinin 1 receptor antagonist; radionuclide chelators; radiopharmaceuticals; kidney uptake; cleavable linkers; neutral endopeptidase (NEP); renal brush border enzymes; prostate-specific membrane antigen (PSMA); cancer imaging and therapy; somatostatin analogs; radiolabeling; radiopharmaceuticals; radionuclide therapy; imaging; adrenergic receptor; positron emission tomography; radiotracer; cholecystokinin-2 receptor; minigastrin; molecular imaging; targeted radiotherapy; lutetium-177; EpCAM; radionuclide; molecular imaging; SPECT; iodine; PIB; breast; cancer; positron emission tomography; PET; target-specific biomolecules; immunoPET imaging pharmaceuticals; production processes; 124I-labeled monoclonal antibodies; cancer; radiolabeling; radiotracers; AAZTA; scandium-44; lutetium-177; FAP; SA; DPP; PREP; radioiodine labeling; radioiodination; radiotracers; biomolecules; peptides; proteins; monoclonal antibodies; radiopharmaceuticals; imaging pharmaceuticals; 123,124,125,131I-labeled molecules and biomolecules; n/a